HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland

BMC Infectious Diseases

Anna Boroń-Kaczmarska¹  Anna Urbańska¹  Dorota Bander¹  Miłosz Parczewski¹ 

[1] Department of Infectious Diseases and Hepatology, Pomeranian Medical University, Szczecin, Poland

关键词: Drug resistance mutations;    Antiretroviral treatment failure;    Raltegravir;    Integrase inhibitors;    HIV-1;   

Others  :  1158663
DOI  :  10.1186/1471-2334-12-368

 received in 2012-08-27, accepted in 2012-12-18,  发布年份 2012

【 摘 要 】

Background

HIV integrase inhibitor use is limited by low genetic barrier to resistance and possible cross-resistance among representatives of this class of antiretrovirals. The aim of this study was to analyse integrase sequence variability among antiretroviral treatment naive and experienced patients with no prior integrase inhibitor (InI) exposure and investigate development of the InI drug resistance mutations following the virologic failure of the raltegravir containing regimen.

Methods

Sequencing of HIV-1 integrase region from plasma samples of 80 integrase treatment naive patients and serial samples from 12 patients with observed virologic failure on raltegravir containing treatment whenever plasma vireamia exceeded >50 copies/ml was performed. Drug resistance mutations were called with Stanford DB database and grouped into major and minor variants. For subtyping bootstrapped phylogenetic analysis was used; Bayesian Monte Carlo Marcov Chain (MCMC) model was implemented to infer on the phylogenetic relationships between the serial sequences from patients failing on raltegravir.

Results

Majority of the integrase region sequences were classified as subtype B; the remaining ones being subtype D, C, G, as well as CRF01_AE , CRF02_AG and CRF13_cpx recombinants. No major integrase drug resistance mutations have been observed in InI-treatment naive patients. In 30 (38.5%) cases polymorphic variation with predominance of the E157Q mutation was observed. This mutation was more common among subtype B (26 cases, 54.2%) than non-B sequences (5 cases, 16.7%), p=0.00099, OR: 5.91 (95% CI:1.77-22.63)]. Other variants included L68V, L74IL, T97A, E138D, V151I, R263K. Among 12 (26.1%) raltegravir treated patients treatment failure was observed; major InI drug resistance mutations (G140S, Q148H and N155H, V151I, E92EQ, V151I, G163R) were noted in four of these cases (8.3% of the total InI-treated patients). Time to the development of drug resistance ranged from 2.6 to 16.3 months with mean increase of HIV viral load of 4.34 (95% CI:1.86-6.84) log HIV-RNA copies/ml at the time of emergence of the major mutations. Baseline polymorphisms, including E157Q were not associated with the virologic failure on raltegravir.

Conclusions

In InI treatment naive patients polymorphic integrase sequence variation was common, with no major resistance mutants. In the treatment failing patients selection of drug resistance occurred rapidly and followed the typical drug resistance pathways. Preexisting integrase polymorphisms were not associated with the treatment failure.

【 授权许可】

   
2012 Parczewski et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, et al.: Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008, 359(4):339-354.
• [2]Gatell JM: The use of integrase inhibitors in treatment-experienced patients. Eur J Med Res 2009, 14(Suppl 3):30-35.
• [3]Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R, et al.: Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci 2011, 1222:83-89.
• [4]Rockstroh JK, Teppler H, Zhao J, Sklar P, Miller MD, Harvey CM, Strohmaier KM, Leavitt RY, Nguyen BY: Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. AIDS 2011, 25(11):1365-1369.
• [5]Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, et al.: Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374(9692):796-806.
• [6]Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, et al.: Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010, 55(1):39-48.
• [7]Correll T, Klibanov OM: Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy 2008, 28(1):90-101.
• [8]Grant P, Zolopa A: Integrase inhibitors: a clinical review of raltegravir and elvitegravir. J HIV Ther 2008, 13(2):36-39.
• [9]Hughes A, Barber T, Nelson M: New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect 2008, 57(1):1-10.
• [10]Boyd M: Dolutegravir–a promising antiretroviral in development. Lancet Infect Dis 2012, 12(2):90-91.
• [11]Blanco JL, Martinez-Picado J: HIV integrase inhibitors in ART-experienced patients. Curr Opin HIV AIDS 2012, 7(5):415-421.
• [12]Cocohoba J, Dong BJ: Raltegravir: the first HIV integrase inhibitor. Clin Ther 2008, 30(10):1747-1765.
• [13]Cotelle P: Patented HIV-1 integrase inhibitors (1998-2005). Recent Pat Antiinfect Drug Discov 2006, 1(1):1-15.
• [14]Miller M: Resistance to integrase inhibitors. J HIV Ther 2007, 12(4):101.
• [15]Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, et al.: Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008, 359(4):355-365.
• [16]Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, Dockx K, Strijbos R, Smits V, Vos A, et al.: Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008, 82(21):10366-10374.
• [17]Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, et al.: Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008, 52(4):1351-1358.
• [18]Roquebert B, Blum L, Collin G, Damond F, Peytavin G, Leleu J, Matheron S, Chene G, Brun-Vezinet F, Descamps D: Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS 2008, 22(15):2045-2046.
• [19]Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N: Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 2009, 23(4):455-460.
• [20]Ferns RB, Kirk S, Bennett J, Cook PM, Williams I, Edwards S, Pillay D: The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 2009, 23(16):2159-2164.
• [21]Canducci F, Marinozzi MC, Sampaolo M, Boeri E, Spagnuolo V, Gianotti N, Castagna A, Paolucci S, Baldanti F, Lazzarin A, et al.: Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. J Antimicrob Chemother 2010, 65(3):425-433.
• [22]Ceccherini-Silberstein F, Malet I, Fabeni L, Dimonte S, Svicher V, D’Arrigo R, Artese A, Costa G, Bono S, Alcaro S, et al.: Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother 2010, 65(11):2305-2318.
• [23]Boyd SD, Maldarelli F, Sereti I, Ouedraogo GL, Rehm CA, Boltz V, Shoemaker D, Pau AK: Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient. Antivir Ther 2011, 16(2):257-261.
• [24]Young B, Fransen S, Greenberg KS, Thomas A, Martens S, St Clair M, Petropoulos CJ, Ha B: Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. Antivir Ther 2011, 16(2):253-256.
• [25]Rhee SY, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, Shafer RW: Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 2008, 5:74. BioMed Central Full Text
• [26]Low A, Prada N, Topper M, Vaida F, Castor D, Mohri H, Hazuda D, Muesing M, Markowitz M: Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother 2009, 53(10):4275-4282.
• [27]Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, Scopelliti F, Pollicita M, Van Wesenbeeck L, Van Eygen V, et al.: Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother 2010, 54(9):3938-3948.
• [28]Ceccherini-Silberstein F, Malet I, D’Arrigo R, Antinori A, Marcelin AG, Perno CF: Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009, 11(1):17-29.
• [29]Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D’Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, et al.: Study of Genotypic and Phenotypic HIV-1 Dynamics of Integrase Mutations During Raltegravir Treatment: A Refined Analysis by Ultra-Deep 454 Pyrosequencing. J Infect Dis 2012, 205(4):557-567.
• [30]Fish MQ, Hewer R, Wallis CL, Venter WD, Stevens WS, Papathanasopoulos MA: Natural polymorphisms of integrase among HIV type 1-infected South African patients. AIDS Res Hum Retroviruses 2010, 26(4):489-493.
• [31]Garrido C, Geretti AM, Zahonero N, Booth C, Strang A, Soriano V, De Mendoza C: Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 2010, 65(2):320-326.
• [32]Charpentier C, Laureillard D, Piketty C, Tisserand P, Batisse D, Karmochkine M, Si-Mohamed A, Weiss L: High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. AIDS 2010, 24(6):867-873.
• [33]Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, de Luca A, Palmisano L, Paraskevis D, Paredes R, Poljak M, Schmit JC, Soriano V, et al.: European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev 2011, 13(2):77-108.
• [34]Van Laethem K, Schrooten Y, Covens K, Dekeersmaeker N, De Munter P, Van Wijngaerden E, Van Ranst M, Vandamme AM: A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J Virol Methods 2008, 153(2):176-181.
• [35]Harrigan PR DW, Wynhoven B, Mo T, Hall T, Galli R: The Performance of ReCall basecalling software for high-throughput HIV drug resistance basecalling using “in-house” methods. 2002. [XIV International AIDS Conference, Spain, Barcelona Abstract #TuPeB4598]
• [36]Liu TF, Shafer RW: Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006, 42(11):1608-1618.
• [37]Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O: New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 2010, 59(3):307-321.
• [38]Posada D: jModelTest: phylogenetic model averaging. Mol Biol Evol 2008, 25(7):1253-1256.
• [39]Drummond AJ, Rambaut A: BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol 2007, 7:214. BioMed Central Full Text
• [40]Tseng A, Foisy M: Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs. Curr Infect Dis Rep 2012, 14(1):67-82.
• [41]Lampiris HW: Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor. Expert Rev Anti Infect Ther 2012, 10(1):13-20.
• [42]Katlama C, Murphy R: Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs 2012, 21(4):523-530.
• [43]Arts EJ, Hazuda DJ: HIV-1 Antiretroviral Drug Therapy. Cold Spring Harb Perspect Med 2012, 2(4):a007161.
• [44]Powderly WG: Integrase inhibitors in the treatment of HIV-1 infection. J Antimicrob Chemother 2010, 65(12):2485-2488.
• [45]Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, Gonzalez CJ, Danovich RM, Wan H, Zhao J, et al.: Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr 2010, 53(4):456-463.
• [46]Turriziani O, Montagna C, Falasca F, Bucci M, Russo G, Lichtner M, Sobze MS, Vullo V, Pistello M, Antonelli G: Analysis of the Integrase Gene from HIV Type 1-Positive Patients Living in a Rural Area of West Cameroon. AIDS Res Hum Retroviruses 2012, 28(12):1729-1733.
• [47]Oliveira MF, Ramalho DB, Abreu CM, Vubil A, Mabunda N, Ismael N, Francisco C, Jani IV, Tanuri A: Genetic Diversity and Naturally Polymorphisms in HIV Type 1 Integrase Isolates from Maputo, Mozambique: Implications for Integrase Inhibitors. AIDS Res Hum Retroviruses 2012, 28(12):1788-1792.
• [48]Nouhin J, Donchai T, Hoang KT, Ken S, Kamkorn J, Tran T, Ayouba A, Peeters M, Chaix ML, Lien TX, et al.: Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naive individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study. Infect Genet Evol 2011, 11(1):38-43.
• [49]Kumar A, Jadhav C: Genotypic prediction of resistant mutation in HIV-1 pol gene towards the antiretroviral drugs. Int J Bioinform Res Appl 2011, 7(1):15-23.
• [50]Varghese V, Liu TF, Rhee SY, Libiran P, Trevino C, Fessel WJ, Shafer RW: HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses 2010, 26(12):1323-1326.
• [51]Goethals O, Vos A, Van Ginderen M, Geluykens P, Smits V, Schols D, Hertogs K, Clayton R: Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology 2010, 402(2):338-346.
• [52]Reuman EC, Bachmann MH, Varghese V, Fessel WJ, Shafer RW: Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob Agents Chemother 2010, 54(2):934-936.
• [53]Saladini F, Meini G, Bianco C, Monno L, Punzi G, Pecorari M, Borghi V, Di Pietro M, Filice G, Gismondo MR, et al.: Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naive and pretreated patients. Clin Microbiol Infect 2012, 18(10):E428-E430.
• [54]Monleau M, Aghokeng AF, Nkano BA, Chaix ML, Peeters M: Drug resistance mutations of HIV-1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-Saharan countries and discordant interpretations. AIDS Res Hum Retroviruses 2012, 28(29):1157-1160.
• [55]Mantovani NP, Azevedo RG, Rabelato JT, Sanabani S, Diaz RS, Komninakis SV: Analysis of Transmitted Resistance to Raltegravir and Selective Pressure among HIV-1-Infected Patients on a Failing HAART in Sao Paulo, Brazil. J Clin Microbiol 2012, 50(6):2122-2125.
• [56]Luu QP, Dean J, Do TT, Carr MJ, Dunford L, Coughlan S, Connell J, Hien NT WWH, Nguyen Thi LA: HIV-1 Coreceptor Tropism, CCR5 Genotype and Integrase Inhibitor Resistance Profiles in Vietnam - Implications for the Introduction of New Antiretroviral Regimens. AIDS Res Hum Retroviruses 2012, 28(10):1344-1348.
• [57]Winslow DL: Resistance to HIV integrase inhibitors. AIDS Alert 2011, 26(9):106-107.
• [58]Phuphuakrat A, Pasomsub E, Kiertiburanakul S, Chantratita W, Sungkanuparph S: HIV Type 1 Integrase Polymorphisms in Treatment-Naive and Treatment-Experienced HIV Type 1-Infected Patients in Thailand Where HIV Type 1 Subtype A/E Predominates. AIDS Res Hum Retroviruses 2011, 28(8):937-943.
• [59]Rangel HR, Garzaro D, Fabbro R, Martinez N, Ossenkop J, Torres JR, Gutierrez CR, Pujol FH: Absence of primary integrase resistance mutations in HIV type 1-infected patients in Venezuela. AIDS Res Hum Retroviruses 2010, 26(8):923-926.
• [60]van Hal SJ, Herring B, Deris Z, Wang B, Saksena NK, Dwyer DE: HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure. Retrovirology 2009, 6:12. BioMed Central Full Text
• [61]Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Belec L, Weiss L, Si-Mohamed A, Piketty C: Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008, 9(9):765-770.
• [62]Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, Wakasa-Morimoto C, Kodama M, Endoh T, Oosugi E, et al.: Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res 2008, 80(2):213-222.
• [63]da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, et al.: HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 2010, 65(6):1262-1269.
• [64]Vavro C, Dudas K, Hasan S, Huang J, Yeo Y, Underwood M: Dolutegravir Treatment of HIV Subjects With Raltegravir Resistance: Integrase Resistance Evolution in Cohort II of the VIKING Study. 2012. [“International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies; June 5-9, 2012; Sitges, Spain”, Abstract 3]
• [65]Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW: HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications. J Infect Dis 2011, 203(9):1204-1214.
• [66]Fransen S, Gupta S, Frantzell A, Petropoulos CJ, Huang W: Substitutions at Amino Acid Positions 143, 148 and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance in vivo. J Virol 2012, 86(13):7249-7255.
• [67]Hu Z, Kuritzkes DR: Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 2010, 55(2):148-155.
• [68]Hatano H, Lampiris H, Fransen S, Gupta S, Huang W, Hoh R, Martin JN, Lalezari J, Bangsberg D, Petropoulos C, et al.: Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr 2010, 54(4):389-393.